BACTI-BNasdaq StockholmHealth CareIFRS · SEK

Bactiguard Holding

Bactiguard Holding AB is a global MedTech company based in Stockholm, Sweden, specializing in the development of biocompatible technology to prevent infections associated with medical devices. The company's proprietary technology involves an ultra-thin noble metal coating that reduces bacterial adhesion and biofilm formation. Bactiguard operates primarily through license partnerships with leading MedTech companies, allowing them to apply its infection prevention technology to their medical devices. The company also offers a portfolio of wound management products, contributing to its mission of reducing patient suffering and combating antimicrobial resistance.

Revenue216m SEK
−10.7 %y/y
Operating profit (EBIT)3.3m SEK
+111.5 %y/y
EBIT margin1.5%
+13.5 ppy/y
Net income7.8m SEK
+126.3 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-200-1000100200300m SEK2021: 169 m SEK2021: EBIT -54 m SEK20212022: 224 m SEK2022: EBIT -56 m SEK20222023: 202 m SEK2023: EBIT -132 m SEK20232024: 242 m SEK2024: EBIT -29 m SEK20242025: 216 m SEK2025: EBIT 3.3 m SEK2025TTM 2026: EBIT 20 m SEKTTM20
RevenueOperating profit (EBIT)TTM = last 12 months, not a full fiscal year

Business

Share of revenue
Infection Prevention Technology60 %

Technology to prevent infections on medical devices.

License Partnerships30 %

Collaborations with MedTech companies to apply technology.

Wound Management Products10 %

Products aimed at wound care and management.

Customers

Bactiguard's customers primarily include global MedTech companies that integrate its infection prevention technology into their medical devices. These companies benefit from enhanced device performance and reduced infection rates, which are critical in healthcare settings. Additionally, healthcare providers and institutions use Bactiguard's wound management products to improve patient outcomes and reduce healthcare costs. The company's focus on partnerships allows it to scale its technology across various medical applications and geographies.

MedTech Companies

Purchase technology for integration into medical devices.

Healthcare Providers

Use wound management products to improve patient care.

Institutional Buyers

Seek solutions to reduce healthcare costs and improve outcomes.

Strategy

Bactiguard's strategic priorities include expanding its license partnerships and increasing the application areas for its infection prevention technology. The company aims to achieve an EBITDA of SEK 200 million by 2030, driven by its scalable business model. Bactiguard is also focusing on enhancing its wound management portfolio, which has shown significant growth. These strategic initiatives are designed to strengthen its market position and address the growing demand for infection prevention solutions.

Expand License PartnershipsMedium term

To increase market reach and application areas.

Achieve SEK 200 million EBITDALong term

To ensure financial growth and stability.

Enhance Wound Management PortfolioShort term

To capture growth in wound care market.

Geography

Bactiguard is headquartered in Stockholm, Sweden, and operates globally through its partnerships with leading MedTech companies. The company’s technology is applied in various regions, enhancing its global presence. Bactiguard's strategic focus on partnerships allows it to penetrate diverse markets, including Europe, North America, and Asia. The company's geographic reach is critical for its growth strategy, enabling it to address infection prevention needs worldwide.

Risks

Bactiguard faces several risks, including dependency on key partnerships and regulatory challenges in different markets. The company's success is closely tied to its ability to maintain and expand its partnerships with MedTech companies. Regulatory approvals can be time-consuming and impact the commercialization of new applications. Additionally, the company is exposed to currency fluctuations due to its global operations. Industry-specific risks include the threat of antimicrobial resistance, which could affect the demand for infection prevention solutions.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Dependency on Partnerships1Currency Fluctuations2Regulatory Challenges3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Dependency on PartnershipsImpact: HighLikelihood: Medium

    Revenue heavily reliant on MedTech collaborations.

  2. Currency FluctuationsImpact: MediumLikelihood: Medium

    Global operations expose to exchange rate risks.

  3. Regulatory ChallengesImpact: MediumLikelihood: Low

    Delays in approvals can impact market entry.

Accounting

Judgemental items
Revenue Recognition

License agreements require careful accounting for royalties.

Impact: Significant on financial results

Currency Fluctuations

Affect reported revenues and require adjustments.

Impact: Material on financial statements

Provisions for Inventory

Estimates impact financial results.

Impact: Critical for accurate assessment

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026

Bactiguard Holding (BACTI-B) Revenue, Earnings & Financials 2025 – Clarifo